Literature DB >> 27619403

The effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) and oxidized low-density lipoprotein, lipid profiles and biomarkers of oxidative stress in patients with polycystic ovary syndrome.

Elham Rahmani1, Mansooreh Samimi2, Faraneh Afshar Ebrahimi2, Fatemeh Foroozanfard2, Shahnaz Ahmadi3, Maryam Rahimi4, Mehri Jamilian5, Esmat Aghadavod6, Fereshteh Bahmani6, Mohsen Taghizadeh6, Mohammad Reza Memarzadeh7, Zatollah Asemi8.   

Abstract

This study was conducted to determine the effects of omega-3 fatty acids and vitamin E co-supplementation on gene expression of lipoprotein(a) (Lp[a]) and oxidized low-density lipoprotein (Ox-LDL), lipid profiles and biomarkers of oxidative stress in women with polycystic ovary syndrome (PCOS). This randomized double-blind, placebo-controlled trial was done on 68 women diagnosed with PCOS according to the Rotterdam criteria aged 18-40 years old. Participants were randomly assigned into two groups to receive either 1000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E supplements (n = 34) or placebo (n = 34) for 12 weeks. Lp(a) and Ox-LDL mRNA levels were quantified in peripheral blood mononuclear cells of PCOS women with RT-PCR method. Lipid profiles and biomarkers of oxidative stress were quantified at the beginning of the study and after 12-week intervention. Quantitative results of RT-PCR demonstrated that compared with the placebo, omega-3 fatty acids and vitamin E co-supplementation downregulated expressed levels of Lp(a) mRNA (P < 0.001) and Ox-LDL mRNA (P < 0.001) in peripheral blood mononuclear cells of women with PCOS. In addition, compared to the placebo group, omega-3 fatty acids and vitamin E co-supplementation resulted in a significant decrease in serum triglycerides (-22.1 ± 22.3 vs. +7.7 ± 23.6 mg/dL, P < 0.001), VLDL- (-4.4 ± 4.5 vs. +1.5 ± 4.7 mg/dL, P < 0.001), total- (-20.3 ± 16.6 vs. +12.2 ± 26.1 mg/dL, P < 0.001), LDL- (-16.7 ± 15.3 vs. +11.9 ± 26.1 mg/dL, P < 0.001) and total-/HDL-cholesterol (-0.5 ± 0.6 vs. +0.4 ± 0.8, P < 0.001). There were a significant increase in plasma total antioxidant capacity (+89.4 ± 108.9 vs. +5.9 ± 116.2 mmol/L, P = 0.003) and a significant decrease in malondialdehyde levels (-0.3 ± 0.4 vs. -0.008 ± 0.6 μmol/L, P = 0.01) by combined omega-3 fatty acids and vitamin E intake compared with the placebo group. Overall, omega-3 fatty acids and vitamin E co-supplementation for 12 weeks in PCOS women significantly improved gene expression of Lp(a) and Ox-LDL, lipid profiles and biomarkers of oxidative stress. Copyright Â
© 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Gene expression; Lipid profiles; Omega fatty acids and vitamin E; Oxidative stress; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2016        PMID: 27619403     DOI: 10.1016/j.mce.2016.09.008

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

1.  PGC-1α protects against oxidized low-density lipoprotein and luteinizing hormone-induced granulosa cells injury through ROS-p38 pathway.

Authors:  Ying Liu; Jianjun Zhai; Jing Chen; Xiaomin Wang; Tingru Wen
Journal:  Hum Cell       Date:  2019-04-16       Impact factor: 4.174

2.  Effects of antioxidant intervention in patients with polycystic ovarian syndrome: A systematic review and meta-analysis.

Authors:  Junde Zhao; Xiaohui Sui; Qingyu Shi; Dan Su; Zhiheng Lin
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 3.  ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases.

Authors:  Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois Eh Smith
Journal:  Am J Clin Nutr       Date:  2017-05-17       Impact factor: 7.045

4.  Association of vitamins, minerals, and lead with Lipoprotein(a) in a cross-sectional cohort of US adults.

Authors:  Eric J Brandt; Daniel J Brandt; Nihar R Desai; Erica S Spatz; Khurram Nasir; Arya Mani
Journal:  Int J Vitam Nutr Res       Date:  2021-05-24       Impact factor: 1.784

5.  The impact of a standardized micronutrient supplementation on PCOS-typical parameters: a randomized controlled trial.

Authors:  Marlene Hager; Kazem Nouri; Martin Imhof; Christian Egarter; Johannes Ott
Journal:  Arch Gynecol Obstet       Date:  2019-05-17       Impact factor: 2.344

Review 6.  N-3 fatty acids as preventive and therapeutic agents in attenuating PCOS complications.

Authors:  Mina Salek; Cain C T Clark; Mohsen Taghizadeh; Sadegh Jafarnejad
Journal:  EXCLI J       Date:  2019-07-25       Impact factor: 4.068

7.  A Pilot Trial: Fish Oil and Metformin Effects on ApoB-Remnants and Triglycerides in Women With Polycystic Ovary Syndrome.

Authors:  Donna Vine; Ethan Proctor; Olivia Weaver; Mahua Ghosh; Katerina Maximova; Spencer Proctor
Journal:  J Endocr Soc       Date:  2021-06-19

8.  A Randomized Double-Blinded, Placebo-Controlled Trial Investigating the Effect of Fish Oil Supplementation on Gene Expression Related to Insulin Action, Blood Lipids, and Inflammation in Gestational Diabetes Mellitus-Fish Oil Supplementation and Gestational Diabetes.

Authors:  Mehri Jamilian; Mansooreh Samimi; Naghmeh Mirhosseini; Faraneh Afshar Ebrahimi; Esmat Aghadavod; Mohsen Taghizadeh; Zatollah Asemi
Journal:  Nutrients       Date:  2018-01-31       Impact factor: 5.717

Review 9.  Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Kailin Yang; Liuting Zeng; Tingting Bao; Jinwen Ge
Journal:  Reprod Biol Endocrinol       Date:  2018-03-27       Impact factor: 5.211

10.  A Comparative Study of the Effect of Flaxseed Oil and Sunflower Oil on the Coagulation Score, Selected Oxidative and Inflammatory Parameters in Metabolic Syndrome Patients.

Authors:  Atefeh Akrami; Elham Makiabadi; Moein Askarpour; Katayoun Zamani; Amir Hadi; Amin Mokari-Yamchi; Siavash Babajafari; Shiva Faghih; Abdollah Hojhabrimanesh
Journal:  Clin Nutr Res       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.